ARTICLE | Clinical News
Angiotech Phase I/II paclitaxel results
February 25, 2000 8:00 AM UTC
ANPI said that in the extended treatment phase of its 29-patient Canadian Phase I/II trial of paclitaxel to treat secondary progressive multiple sclerosis, 95 percent of patients remained stable or im...